An Open-Label, Multicenter, Randomized Study of Combination Therapy With Oral Telbivudine Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-Positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant.

Trial Profile

An Open-Label, Multicenter, Randomized Study of Combination Therapy With Oral Telbivudine Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-Positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2011

At a glance

  • Drugs Adefovir dipivoxil; Telbivudine
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Idenix Pharmaceuticals; Novartis
  • Most Recent Events

    • 21 Jul 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Actual initiation date changed from Sep 2006 to Jan 2007 as reported by ClinicalTrials.gov.
    • 25 Nov 2008 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top